Disease model of induced pluripotent stem cell (IPSC)-derived type 2 diabetes mellitus, associated with coronary artery disease
Patent Information
- Application Number
- EP2022811757
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-05-25
- Filing Date
- 2022-05-18
- Publication Date
- 2024-11-27
AI Technical Summary
Current drug research for diabetes mellitus and associated coronary artery disease is hindered by high costs, lengthy development processes, and inefficiencies due to reliance on animal models and the lack of reliable, high-quality human iPSC-derived disease models, which are expensive and logistically challenging to access, leading to ineffective or harmful drug molecules and limited therapeutic success.
Development of a cost-effective, timely-accessed iPSC-derived disease model for type 2 diabetes mellitus associated with coronary artery disease, utilizing pluripotent stem cells to create a human-relevant model for drug efficacy and safety testing, reducing the need for animal models and enabling personalized treatment approaches.
Facilitates efficient drug development by providing a reliable, cost-effective, and safe human-relevant disease model for diabetes and coronary artery disease research, reducing health expenditures and enabling personalized treatment strategies, while ensuring product quality and stability.
Abstract
Description
[0001] DISEASE MODEL OF INDUCED PLURIPOTENT STEM CELL (iPSC)-DERIVED TYPE 2 DIABETES MELLITUS, ASSOCIATED WITH CORONARY ARTERY DISEASE
[0002] Technical field of the invention
[0003] The invention relates to a disease model of induced pluripotent stem cell (iPSC)-derived type 2 Diabetes Mellitus, associated with coronary artery disease.
[0004] State of art
[0005] The prevalence of diabetes is in terms of the numbers that are considered epidemic in countries. There are 374 million patients diagnosed with hidden diabetes (pre-diabetes). This population is expected to reach 578 million people by 2030. The global adult diabetes patient population (age range 20-79) is 463 million (9.3% of the world population), according to the numbers of the International Diabetes Federation (IDF). According to the information provided in the Prevalence Study of Diabetes, Hypertension, Obesity and Endocrinological Diseases-ll (TURDEP-II Study), diabetes ratio is 13.7% in Turkey. The frequency of diabetes has been reported to increase by 90% and obesity by 44% in the last 12 years.
[0006] Drug research is a challenging process that lasts for many years and creates a serious financial burden on researchers. The challenging adventure of a drug molecule from its proof-of-concept phase to its clinical use sometimes leads to a late understanding that the molecule in question is ineffective or harmful as the phases are proceeded. Meanwhile, a large number of animal and human populations will have already been researched. In addition, since there are significant differences between animal and human organisms, molecules sometimes do not manifest the exact profile they present in the animal models or as they should in humans. The early trial of drug molecules in human- or animal-based in vitro models has a great advantage in terms of health expenditures, public health and access to the right treatments.
[0007] IPSCs are cells that have embryonic stem cell-like function and are obtained as a result of reprogramming the matured somatic cells as if they were going back to the future in a time machine, with the use of specific transcription factors. Thanks to these characteristics, they can be used in the treatment of many degenerative and genetic diseases. IPSCs were first obtained from mice in 2006, and then from humans in 2007. IPSCs have many features in common with embryonic stem cells. The most important of these is the capacity to renew itself and to be able to plurally differentiate into all cell types in the human body. The increasing capacity of human-based iPSC banking in the world has begun to serve the easy delivery of characterized and quality-controlled stem cell lines to a wide range of global researchers. The reputation of iPSCs is increasing day by day in terms of modeling and investigating human diseases, and even in terms of monitoring drugs. Thus, researchers have the chance to access tissues that are obtained once but can be expanded many times. It is impossible for researchers who cannot access iPSCs to study new treatment approaches on the disease models closest to humans. Thus, studies on new therapies are not sufficient or sufficiently successful, and patients cannot be absolutely healed at the end of the day. In addition, the development of cellular therapies that can be produced by the use of iPSCs becomes equally impossible. These products are usually sourced from abroad, as such technologies should be used.
[0008] IPSC-derived disease models are among the health products in the medical device category. The primary need for iPSCs is the development of these products for disease modeling purposes. However, these centers develop iPSC-derived cellular therapies as a treatment approach. Since the relevant legislation has not yet been completed, the products are placed on the market without a license.
[0009] Although great success has recently been achieved by modeling a certain number of diseases in petri dishes, the most common problems encountered in disease models developed in petri dishes are the lack of quality criteria, the inability to maintain cell stability in terms of genetics, expensive sales prices, international logistical difficulties in the supply of products and the fact that the products accessed are not as reliable as declared. Therefore, iPSC-derived disease models are not yet released to the market in a sufficiently high quality and safe way in the world. Meanwhile, users do not know how effective the products they buy will be. The sales of products with very high costs from one country to another limit the possibilities for countries with low purchasing power.
[0010] Retention of products at customs crossings causes users to postpone their research.
[0011] Patent research has been conducted on the subject of the invention, for example, application number WO2016100857 is related to the use of stem cells in creating a type 2 diabetes model. Following the invention that emerged in 2006 to transform adult stem cells into embryonic phases with transcription factors, many patents were granted to develop iPSC isolation, conditioning, iPSC-derived disease modalities and treatment approaches. However, there was no patent for the diabetes model associated with coronary artery disease.
[0012] Technical problems to be solved bv the invention
[0013] With this invention, by creating a Diabetes Mellitus disease model associated with coronary artery disease it is aimed to present a timely-accessed, cost-effective solution to researchers and large-small-medium-sized pharmaceutical companies conducting antidiabetic drug R&D studies in order to facilitate the execution of efficacy and safety studies in the development of new drug molecules from the proof-of-concept phase, to prevent unnecessary R&D costs and to foster the use of fewer animals as disease models. It is predicted that iPSC technology, which is very important in terms of studying human cell-derived disease models and developing new approaches to new drugs and cell treatment, will also reduce health expenditures as it allows the development of personalized treatment methods.
[0014] Description of the invention
[0015] With this invention, by creating a Diabetes Mellitus disease model associated with coronary artery disease from the stimulated pluripotent stem cell source, it is aimed to present a timely-accessed, cost-effective solution to researchers and small-medium-sized pharmaceutical companies conducting antidiabetic drug R&D studies in order to facilitate proceeding from the proof-of-concept phase, to prevent unnecessary R&D costs and to foster the use of fewer animals as disease models.
[0016] Detailed description of the invention:
[0017] The prevalence of diabetic patients with coronary artery disease reaches up to 50% in most countries. Diabetes Mellitus and coronary artery disease are closely related through multiple risk factors. Among adults with Diabetes Mellitus, there is a prevalence of 75% to 85% of hypertension, 70% to 80% for high levels of low-density lipoprotein (LDL), and 60% to 70% for obesity. The prevalence of Diabetes Mellitus and coronary artery disease increases primarily due to the increased prevalence of obesity. Cholesterol plays an important role in determining the physicochemical properties and functions of the cell membrane. A suitable membrane structure is critical in pancreatic b cells for glucose-mediated insulin secretion, and changes in cellular cholesterol content may adversely affect this process, leading to cellular dysfunction. The LDL receptor (LDL-R) appears to play an important role in b-cell dysfunction due to cholesterol accumulation.
[0018] Pancreatic b-cell dysfunction is associated with glucose fluctuation and results in endothelial damage in coronary artery patients. Endothelial dysfunction is generally present in diabetic patients with coronary artery disease, as evidenced by elevated endothelial 1 levels and low nitric oxide levels. Vascular endothelial (VE)-cadherin has been identified as an updated endothelial function marker that correlates well with endothelin 1 in diabetic patients with recent coronary artery disease. Growth factor A (VEGF-A) is mainly produced by a and b cells, and functions as a key regulator of islet microvasculature. VEGF-A knockout in insulin- producing cells results in islet hypovascularization, loss of endothelial fenestrations, and reduced glucose clearance and glucose-induced insulin secretion. Strict control of VEGF-A expression is necessary for islet vessel repair and glucose homeostasis. VEGF-A loss of function results in islet hypovascularization and impaired glucose tolerance, while long-term VEGF overexpression results in islet hypervascularization, beta cell death, and open diabetes.
[0019] Among the patients with type 2 diabetes in the studies related to the subject of the invention; the selected ones are those whose fasting blood glucose, postprandial blood glucose, HbAlc, lipid profiles, electrolytes, liver and kidney function tests have been examined, whose first diagnosis date is not more than 5 years ago, whose body mass index (BMI) is between 20- 30 kg / m2, who do not use insulin, who use dual and triple oral antidiabetic drugs, one of which is metformin.
[0020] In the first stage, donor tissue was transferred from the endocrinology and metabolic diseases clinic. After the blood tests of the donors and their histories obtained from the clinics were examined, the donor tissues deemed appropriate were kept in the storage area until the studies started. Peripheral blood samples from healthy human donors, those with diabetes and coronary heart disease were collected to obtain mononuclear cells.
[0021] The blood components taken from the patients were cultured in the differentiation media, and the cells were given an embryonic stem cell-like pluripotent feature with four OSKM transcription factors (Oct4, Sox2, Klf4 and L-Myc). Pluripotent marker analyses were confirmed by immunofluorescence staining of surface and intracellular antigens. Inverted microscope images were taken to determine proliferation and differentiation capacities and gene expression levels were measured by qRT-PCR technique. With in vitro differentiation, pancreatic b cells were programmed. For the diabetes model, low-glucose media was used, and the glucose reuptake capacity in the cells was evaluated by checking the gene expression levels of hypertrophy markers NPPB and NPPA and insulin-dependent glucose carrier GLUT4. After using 2% oxygen, 10 mg / ml glucose and 0% fetal bovine serum (FBS) for imitation of the ischemic environment, membrane damage and decreased cell viability rate were determined by staining with propidium iodide. By checking the extent to which IL-8 affects the increase in mRNA expression, the suitability of ischemic conditioning for in vivo conditions was examined. Sterility, cell count, vitality, and characterization studies were conducted separately in both disease models. Then, diabetes and ischemia models were combined with each other, and at this stage, differentiation, proliferation and characterization studies and confirmation studies of the method developed were performed.
[0022] By knocking out VEGF-A in insulin-producing cells, islet hypovascularization, loss of endothelial fenestrations, and decreased glucose clearance and glucose-induced insulin secretion were carried out. Pancreatic b-cell dysfunction was carried out through glucose fluctuation. Accompanying coronary artery disease was confirmed by measurement of VE- cadherin and endothelin 1 (when high) and nitric oxide (when low) levels.
[0023] Product safety was confirmed by the following tests; Insulin resistance (detection of reduced insulin signaling with a decrease in Akt phosphorylation), Metabolic shift (detection by reduced glucose oxidation and increased fatty acid oxidation), Lipotoxicity (detection by increased intracellular lipid accumulation and / or increased lipid peroxidation), Hypertrophy (detection by hypertrophic morphological examinations and / or increased BNP marker expression), Manipulated function (detection by impaired Ca2+ transition or contractility and / or mitochondrial dysfunction), Cell proliferation and differentiation (cell proliferation, flow cell measurement), Viability and characterization (detection of viability on the face by flowing cell measurement), and Contamination (mycoplasma test).
[0024] IPSCs are an important component of regenerative medicine practices that allow human diseases to be constructed in small plastic containers under laboratory conditions. Obtained in line with specific quality and stability standards, iPSC-derived disease models, with the ability to mimic the human organism, become the most appropriate setting for early-stage testing of drug molecules. IPSC-derived disease models provide an advantage by helping to reduce the burden not only in the early stages of drug research but also in every stage of the molecules’ journey to the clinic. Thus, it appears as a safe alternative with the need for fewer animal models and fewer human trials. Universities, hospitals, research centers and companies that plan to develop new treatment approaches to diabetes constitute the target audience of the product subject to this invention. Today, more than two hundred clinical research studies are being carried out in Turkey for the treatment of diabetes. In addition, there are more than one hundred clinical studies conducted to treat coronary heart diseases in Turkey. These studies have led to the fact that these two diseases are among the top 10 most studied diseases in Turkey.
[0025] Developed patient- and disease-specific iPSCs facilitate new drug testing and studies and accelerate pharmacological and toxicological studies. Thus, products that can be used quickly in outbreak situations such as the recent COVID-19 can be developed.
[0026] IPSC-derived disease models include endless cell lines. In other words, by obtaining the cell line produced once by the customer, it is possible to benefit from the product by reproducing over that line many times.
[0027] The iPSC disease model, as mentioned above, is the appropriate technology for all new treatment approaches being developed for diabetic diseases.
[0028] With this invention, it will be possible to conduct disease-specific and personalized research and develop therapeutic strategies. In particular, this will help to develop innovative treatments by enabling research into situations that are impossible or difficult to investigate due to the limited amount of material taken from the child or the inability to do so. This provides users with advantages in terms of financial return and therapeutic potential. Meanwhile, the quality criteria experienced in disease models have not been determined, cell stability cannot be preserved in terms of genetics, expensive sales costs, international logistical difficulties in the supply of products and the fact that the products accessed are not as reliable as declared will be solved.
Claims
CLAIMS1. A Disease Model of induced pluripotent stem cells (iPSC)-derived type 2 DiabetesMellitus, associated with coronary artery disease, characterized in that; it is obtained by the following method steps- In the first stage, transferring donor tissue with endocrinology and metabolic diseases,- Obtaining mononuclear cells by taking peripheral blood from healthy human donors, those with diabetes and coronary heart disease,- Culturing the blood components taken from the patients in the differentiation media, giving the cells an embryonic stem cell-like pluripotent feature with four transcription factors (Oct4, Sox2, Klf4 and L-Myc),- Confirming pluripotent marker analysis by immunofluorescence staining of surface and intracellular antigens,- Taking inverted microscope images for the determination of proliferation and differentiation capacities and measuring gene expression levels by qRT-PCR technique,- Programming pancreatic b cells with in vitro differentiation,- Using low-glucose media for the diabetes model,- Evaluating glucose reuptake capacity in cells by checking the gene expression levels of hypertrophy markers NPPB and NPPA and insulin-dependent glucose carrier GLUT4,- Determining membrane damage and decreased cell viability rate by staining with propidium iodide after using 2% oxygen, 10 mg / ml glucose and 0% fetal bovine serum (FBS) for imitation of the ischemic environment,- Examination of the suitability of ischemic conditioning for in vivo conditions by checking the extent to which IL-8 affects the increase in mRNA expression,- Performing sterility, cell count, vitality, characterization studies separately in both disease models,- Then, carrying out differentiation, proliferation, and characterization studies at this stage, by combining diabetes and ischemia models with each other,- By knocking out VEGF-A in insulin-producing cells, carrying out islet hypovascularization, loss of endothelial fenestrations and reduced glucose clearance and glucose-induced insulin secretion,- Carrying out pancreatic b cell dysfunction through glucose fluctuation,Confirmation of accompanying coronary artery disease by measurement of VE- cadherin and endothelin 1 (in case of high) and nitric oxide (in case of low) levels.
2. A product according to claim 1 , characterized in that; it is administered to the patients with type 2 diabetes; especially to those whose fasting blood glucose, postprandial blood glucose, HbAlc, lipid profiles, electrolytes, liver and kidney function tests have been examined, whose first diagnosis date is not more than 5 years ago, whose BMI is between 20-30 kg / m2, who do not use insulin, who use dual and triple oral antidiabetic drugs, one of which is metformin.
3. A product according to claim 1 , characterized in that; it is confirmed using the following tests- Insulin resistance (detection of reduced insulin signaling with a decrease in Akt phosphorylation),- Metabolic shift (detection by reduced glucose oxidation and increased fatty acid oxidation),- Lipotoxicity (detection by increased intracellular lipid accumulation and / or increased lipid peroxidation),- Hypertrophic (detection by hypertrophic morphological examinations and / or increased BNP marker expression),- Manipulated function (detection by impaired Ca2+ transition or contractility and / or mitochondrial dysfunction),- Cell proliferation and differentiation (cell count, flowing cell measurement),- Viability and characterization (detection of the percentage of viability by flowing cell measurement),- Contamination (mycoplasma test).
